Short Interest in CytoMed Therapeutics Limited (NASDAQ:GDTC) Increases By 9.9%

CytoMed Therapeutics Limited (NASDAQ:GDTC) was the target of a significant increase in short interest in June. As of June 15th, there was short interest totalling 38,800 shares, an increase of 9.9% from the May 31st total of 35,300 shares. Based on an average trading volume of 4,500 shares, the short-interest ratio is presently 8.6 days. Currently, 0.8% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, Benchmark reaffirmed a “speculative buy” rating and issued a $5.00 target price on shares of CytoMed Therapeutics in a report on Tuesday, June 11th.

CytoMed Therapeutics Stock Performance

GDTC stock opened at $2.04 on Thursday. CytoMed Therapeutics has a 52 week low of $1.89 and a 52 week high of $9.25. The company’s 50-day moving average price is $2.07 and its 200 day moving average price is $2.65. The company has a debt-to-equity ratio of 0.04, a current ratio of 14.09 and a quick ratio of 14.09.

About CytoMed Therapeutics

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity.